MX389786B - Derivados de 4-metil 7-{[5-heterociclilpirazina-2-il]amino}1,2- dihidro-1,6-naftiridina-5-ona como compuestos inhibidores de cdk4/6 y el uso de los mismos para el tratamiento de cáncer. - Google Patents

Derivados de 4-metil 7-{[5-heterociclilpirazina-2-il]amino}1,2- dihidro-1,6-naftiridina-5-ona como compuestos inhibidores de cdk4/6 y el uso de los mismos para el tratamiento de cáncer.

Info

Publication number
MX389786B
MX389786B MX2019006843A MX2019006843A MX389786B MX 389786 B MX389786 B MX 389786B MX 2019006843 A MX2019006843 A MX 2019006843A MX 2019006843 A MX2019006843 A MX 2019006843A MX 389786 B MX389786 B MX 389786B
Authority
MX
Mexico
Prior art keywords
cdk4
inhibitor
compounds
disclosed
isomers
Prior art date
Application number
MX2019006843A
Other languages
English (en)
Other versions
MX2019006843A (es
Inventor
Charles Z Ding
Lihong Hu
Shuhui Chen
Zhaobing Xu
Original Assignee
Cstone Pharmaceuticals Shanghai Co Ltd
Cstone Pharmaceuticals
Cstone Pharmaceuticals Suzhou Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cstone Pharmaceuticals Shanghai Co Ltd, Cstone Pharmaceuticals, Cstone Pharmaceuticals Suzhou Co Ltd filed Critical Cstone Pharmaceuticals Shanghai Co Ltd
Publication of MX2019006843A publication Critical patent/MX2019006843A/es
Publication of MX389786B publication Critical patent/MX389786B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describe una serie de compuestos que actúan como inhibidores de CDK4/6. Se describen específicamente compuestos como los representados por la fórmula (I), sales o isómeros farmacéuticamente aceptables de estos, composiciones farmacéuticas que los contienen y el uso de estos en la preparación de fármacos para tratar cánceres.
MX2019006843A 2016-12-16 2017-12-15 Derivados de 4-metil 7-{[5-heterociclilpirazina-2-il]amino}1,2- dihidro-1,6-naftiridina-5-ona como compuestos inhibidores de cdk4/6 y el uso de los mismos para el tratamiento de cáncer. MX389786B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201611170508 2016-12-16
CN201710787583 2017-09-04
PCT/CN2017/116611 WO2018108167A1 (zh) 2016-12-16 2017-12-15 Cdk4/6抑制剂

Publications (2)

Publication Number Publication Date
MX2019006843A MX2019006843A (es) 2019-11-11
MX389786B true MX389786B (es) 2025-03-20

Family

ID=62558021

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019006843A MX389786B (es) 2016-12-16 2017-12-15 Derivados de 4-metil 7-{[5-heterociclilpirazina-2-il]amino}1,2- dihidro-1,6-naftiridina-5-ona como compuestos inhibidores de cdk4/6 y el uso de los mismos para el tratamiento de cáncer.

Country Status (12)

Country Link
US (1) US10676474B2 (es)
EP (1) EP3556758B1 (es)
JP (1) JP7044801B2 (es)
KR (1) KR102513448B1 (es)
CN (1) CN110382495B (es)
AU (1) AU2017374721B2 (es)
IL (1) IL267299B (es)
MX (1) MX389786B (es)
RU (1) RU2747311C2 (es)
SA (1) SA519402103B1 (es)
TW (1) TWI749126B (es)
WO (1) WO2018108167A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102513448B1 (ko) * 2016-12-16 2023-03-23 씨스톤 파마슈티컬즈 Cdk4/6 억제제
CN112292379B (zh) * 2018-06-13 2022-03-04 基石药业（苏州）有限公司 吡啶并吡啶酮衍生物的盐型及晶型
WO2021003314A1 (en) * 2019-07-02 2021-01-07 Nuvation Bio Inc. Heterocyclic compounds as kinase inhibitors
WO2021110122A1 (zh) * 2019-12-05 2021-06-10 基石药业（苏州）有限公司 Cdk4/6抑制剂的组合疗法
US20230135215A1 (en) * 2020-02-28 2023-05-04 Fochon Biosciences, Ltd. Compounds as cdk2/4/6 inhibitors
AR124154A1 (es) 2020-11-27 2023-02-22 Rhizen Pharmaceuticals Ag Inhibidores de cdk
WO2022149057A1 (en) 2021-01-05 2022-07-14 Rhizen Pharmaceuticals Ag Cdk inhibitors
CN116063307B (zh) * 2021-10-29 2025-08-19 中国药科大学 Shp2与cdk4/6双靶点抑制化合物合成及其制备方法与应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ502704A (en) * 1997-08-20 2002-06-28 Warner Lambert Co Naphthyridinones and pharmaceuticals thereof and their use in inhibiting cellular proliferation and protein tyrosine kinase or cell cycle kinase enzymatic activity
DE60303009T2 (de) 2002-01-22 2006-07-13 Warner-Lambert Co. Llc 2-(pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-one
IS7839A (is) * 2002-11-22 2004-05-23 Merck Frosst Canada Ltd. 4-oxó-1-(3-setið fenýl-1,4-díhýdró-1,8-naftýridín-3-karboxamíð fosfódíesterasa-4 hindrar
WO2005094830A1 (en) 2004-03-30 2005-10-13 Pfizer Products Inc. Combinations of signal transduction inhibitors
MXPA06014021A (es) 2004-06-04 2007-02-08 Pfizer Prod Inc Procedimiento para tratar crecimiento celular anormal.
RU2009108006A (ru) 2006-09-08 2010-10-20 Пфайзер Продактс Инк. (Us) Синтез 2-(пиридин-2-иламино)-пиридо[2, 3-d]пиримидин-7-онов
MX2010010975A (es) 2008-04-07 2010-11-01 Amgen Inc Amino piridinas/pirimidinas gem-disustituidas y espirociclicas como inhibidores de ciclo celular.
PA8852901A1 (es) 2008-12-22 2010-07-27 Lilly Co Eli Inhibidores de proteina cinasa
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
AU2011240735B2 (en) 2010-04-13 2015-01-29 Novartis Ag Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase (CDK4/6) inhibitor and an mTOR inhibitor for treating cancer
DK2600719T3 (da) 2010-08-05 2014-12-15 Univ Temple 2-substituerede 8-alkyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-6-carbonnitriler og anvendelser deraf
PT2688887E (pt) 2011-03-23 2015-07-06 Amgen Inc Inibidores duais tricíclicos fusionados de cdk 4/6 e flt3
CN104812756A (zh) 2012-09-26 2015-07-29 曼凯德公司 多激酶通路抑制剂
PL2958916T3 (pl) 2013-02-21 2019-01-31 Pfizer Inc. Stałe postacie selektywnego inhibitora CDK4/6
WO2014183520A1 (zh) 2013-05-17 2014-11-20 上海恒瑞医药有限公司 吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用
WO2016015598A1 (en) * 2014-07-26 2016-02-04 Sunshine Lake Pharma Co., Ltd. 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as cdk inhibitors and uses thereof
CN105130986B (zh) * 2015-09-30 2017-07-18 广州科擎新药开发有限公司 嘧啶或吡啶并吡啶酮类化合物及其应用
JP6951767B2 (ja) * 2015-12-13 2021-10-20 ハンジョウ イノゲート ファーマ カンパニー リミテッドＨａｎｇｚｈｏｕ Ｉｎｎｏｇａｔｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． 抗癌薬として使用される複素環式化合物
KR102513448B1 (ko) * 2016-12-16 2023-03-23 씨스톤 파마슈티컬즈 Cdk4/6 억제제

Also Published As

Publication number Publication date
WO2018108167A1 (zh) 2018-06-21
IL267299B (en) 2022-09-01
EP3556758B1 (en) 2024-07-17
CA3046864A1 (en) 2018-06-21
JP2020510083A (ja) 2020-04-02
RU2019121926A3 (es) 2021-01-18
EP3556758A1 (en) 2019-10-23
AU2017374721A1 (en) 2019-08-01
KR102513448B1 (ko) 2023-03-23
KR20190092549A (ko) 2019-08-07
MX2019006843A (es) 2019-11-11
US10676474B2 (en) 2020-06-09
JP7044801B2 (ja) 2022-03-30
CN110382495A (zh) 2019-10-25
BR112019012176A2 (pt) 2019-11-05
AU2017374721B2 (en) 2021-02-25
RU2747311C2 (ru) 2021-05-04
SA519402103B1 (ar) 2022-04-05
EP3556758A4 (en) 2019-10-23
RU2019121926A (ru) 2021-01-18
TWI749126B (zh) 2021-12-11
TW201823246A (zh) 2018-07-01
US20190315745A1 (en) 2019-10-17
EP3556758C0 (en) 2024-07-17
IL267299A (es) 2019-07-31
CN110382495B (zh) 2022-04-05

Similar Documents

Publication Publication Date Title
SA519410865B1 (ar) مركب حلقي شبيه بكُومارين بوصفه مثبط mek واستخدامه
SA519402103B1 (ar) 1,6-naphthyridine مشتقات 1، 6 نفثيرايدين CDK4/6 على شكل مثبط
PH12020551717A1 (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
MX2016016516A (es) Inhibidores de fosfatidilinositol 3-cinasa.
ZA202201499B (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
MX2016016530A (es) Inhibidores de fosfatidilinositol 3-quinasa.
MX2016016538A (es) Derivados de quinazolinona como inhibidores de fosfatidilinositol 3-cinasa.
UA118233C2 (uk) Сполуки, які інгібують білок mcl-1
MX347988B (es) Inhibidores de fosfatidilinositol 3-cinasa.
MD20170016A2 (ro) Compuşi aminopirimidinici ca inhibitori JAK
GEAP201914680A (en) New hydroxyacid derivatives, a process for their preparation and pharmaceutical compositions containing them
MX2016016528A (es) Inhibidores de fosfatidilinositol 3-quinasa.
MX2020001717A (es) Inhibidores macrociclicos de mcl-1 y metodos de uso.
BR112016015983A2 (pt) Compostos de indazol como inibidores de irak4, seus usos, e composição farmacêutica
WO2015191754A3 (en) Phosphatidylinositol 3-kinase inhibitors
MX2020010942A (es) Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales.
PH12016502539A1 (en) Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators
MX2020001531A (es) Nuevos compuestos hetorociclicos como inhibidores de cdk8/19.
SA522431777B1 (ar) مشتقات ألفا -d- جالاكتو بيرانوسيد
AU2017269673A1 (en) Pyridine dicarboxamide derivatives as bromodomain inhibitors
TR201819805T4 (tr) Flavaglin türevleri̇.
MX2022000390A (es) Derivados macrociclicos espirociclicos como inhibidores de mcl-1.
MX379327B (es) Derivados de piridinilo, composiciones farmaceuticas y sus usos como inhibidores aoc3
AU2018264313A1 (en) Indolizine derivatives and application thereof in medicine
MX2017002544A (es) Derivados de isoquinolinona utiles en el tratamiento contra el cancer.